Showing results (961-970 of 5,269) with videos related to

Sort By:
Pageof 527
European Journal of Haematology|July 23, 2021
Safety of outpatient stem cell mobilization with low- or intermediate-dose cyclophosphamide in newly diagnosed multiple myeloma patientsAlessandra Pompa, Loredana Pettine, Diana Giannarelli, et al.
European Journal of Haematology|May 20, 2022
Acquired aplastic anemia following SARS-CoV-2 vaccinationAlexander Röth, Stefanie Bertram, Thomas Schroeder, et al.
European Journal of Haematology|July 1, 2022
Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and ItalyKatja Weisel, Astrid Ottosson Wadlund, Guntug Gungor, et al.
European Journal of Haematology|February 21, 2008
Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemiaJochen Greiner, Michael Schmitt
European Journal of Haematology|February 21, 2008
Age-matched lymphocyte subpopulation reference values in childhood and adolescence: application of exponential regression analysisSabine Huenecke, Michael Behl, Carla Fadler, et al.
European Journal of Haematology|January 10, 2008
Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: practical issuesEsa Jantunen, Taru Kuittinen
European Journal of Haematology|January 10, 2008
Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide dosesP S Haas, U Denz, G Ihorst, et al.
European Journal of Haematology|April 1, 1991
Recombinant interferon-gamma inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitroH Jernberg-Wiklund, M Pettersson, K Nilsson
European Journal of Haematology|August 27, 2019
Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugsMichał Witkowski, Magdalena Witkowska, Tadeusz Robak
European Journal of Haematology|January 29, 2021
Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapyPamela Abdayem, Nathalie Ibrahim, Yolla El Dakdouki, et al.
Pageof 527